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ABSTRACT Group A Streptococcus (GAS) infections account for an estimated
500,000 deaths every year. This bacterial pathogen is responsible for a variety of
mild and life-threatening infections and the triggering of chronic autoimmune se-
quelae. Pharyngitis caused by group A Streptococcus (GAS), but not asymptomatic
GAS carriage, is a prerequisite for acute rheumatic fever (ARF). Repeated bouts of
ARF may trigger rheumatic heart disease (RHD), a major cause of heart failure and
stroke accounting for 275,000 deaths annually. A vaccine that prevents pharyngitis
would markedly reduce morbidity and mortality from ARF and RHD. Nonhuman pri-
mates (NHPs) have been utilized to model GAS diseases, and experimentally infected
rhesus macaques develop pharyngitis. Here we use an NHP model of GAS pharyngi-
tis to evaluate the efﬁcacy of an experimental vaccine, Combo5 (arginine deiminase
[ADI], C5a peptidase [SCPA], streptolysin O [SLO], interleukin-8 [IL-8] protease
[SpyCEP], and trigger factor [TF]), speciﬁcally designed to exclude GAS components
potentially linked to autoimmune complications. Antibody responses against all
Combo5 antigens were detected in NHP serum, and immunized NHPs showed a re-
duction in pharyngitis and tonsillitis compared to controls. Our work establishes the
NHP model as a gold standard for the assessment of GAS vaccines.
IMPORTANCE GAS-related diseases disproportionally affect disadvantaged popu-
lations (e.g., indigenous populations), and development of a vaccine has been
neglected. A recent strong advocacy campaign driven by the World Health Orga-
nization and the International Vaccine Institute has highlighted the urgent need
for a GAS vaccine. One signiﬁcant obstacle in GAS vaccine development is the
lack of a widely used animal model to assess vaccine efﬁcacy. Researchers in the
ﬁeld use a wide range of murine models of infection and in vitro assays, some-
times yielding conﬂicting results. Here we present the nonhuman primate pha-
ryngeal infection model as a tool to assess vaccine-induced protection against
colonization and clinical symptoms of pharyngitis and tonsillitis. We have tested
the efﬁcacy of an experimental vaccine candidate with promising results. We be-
lieve that the utilization of this valuable tool by the GAS vaccine research com-
munity could signiﬁcantly accelerate the realization of a safe and effective GAS
vaccine for humans.
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Acute rheumatic fever (ARF) leading to rheumatic heart disease (RHD) causessigniﬁcant global morbidity and mortality, with an estimated prevalence of 32
million cases, resulting in 275,000 deaths each year (1, 2). With over 2.4 million cases in
children, RHD is the most common pediatric heart afﬂiction (3, 4). It is well established
on clinical and epidemiological grounds that group A Streptococcus (GAS) (Streptococ-
cus pyogenes) pharyngitis is a precursor for ARF (5). A vaccine to address the global
burden of ARF and RHD must therefore reduce GAS pharyngitis (6); however, a safe and
effective commercial vaccine for this purpose is lacking. Obstacles hindering GAS
vaccine development include strain diversity, antigenic variation, differences in the
geographical distribution of serotypes, and the potential for GAS antigens to trigger
autoimmune sequelae, including rheumatic fever (7). In 1979, the U.S. Food and Drug
Administration placed a ban on GAS vaccine development research using human
subjects that lasted two and a half decades. The 2004 workshop instrumental in lifting
this moratorium implicated structural features of the surface-anchored M protein and
the N-acetylglucosamine (GlcNAc) side chain of the species-deﬁning cell wall group A
carbohydrate (GAC) in molecular mimicry of host components, potentially provoking
autoimmunity and development of ARF (8). As one consequence of the earlier FDA
moratorium, only a limited number of GAS vaccine candidates have progressed to
phase I and II clinical trials, and to date, evidence for potential vaccine-induced
protection stems only from preclinical studies using rodents and in vitro assays (9–11).
Pharyngitis, the most common GAS disease manifestation in humans, cannot be
reproduced in mice. However, spontaneous GAS pharyngeal carriage in rhesus ma-
caques has been documented (12). Nonhuman primates (NHPs) experimentally infected
with GAS in the upper respiratory tract develop pharyngitis and tonsillitis clinical signs
such as erythema, palatal petechiae, and occlusion of the oropharyngeal space (13, 14).
Here we report the development of a pharyngeal infection model in rhesus macaques
to assess vaccine efﬁcacy against GAS pharyngitis and evaluation of the protective
efﬁcacy a non-M-protein-based vaccine candidate (Combo5) in the NHP model.
RESULTS AND DISCUSSION
This work presents the NHP pharyngeal infection model as a valuable tool to
advance GAS vaccine research. Pharyngitis, the most common GAS disease manifesta-
tion, which is prerequisite for the development of ARF, cannot be modeled in mice.
Pharyngitis is also relevant as it represents a potential clinical endpoint in a clinical trial
setting for GAS vaccine candidates. In order to optimize GAS pharyngeal infection in
NHPs, we ﬁrst performed a small pilot experiment to determine the GAS infecting dose
that yielded colonization of the upper respiratory tract and development of pharyngitis
and tonsillitis clinical signs. We used the representative GAS M1T1 5448 strain; the GAS
M1T1 clone is prevalent and globally disseminated, responsible for both mild and
severe infections (15). Under anesthesia, two NHPs were intranasally infected with
either 1 107 or 5 107 CFU of GAS M1T1 5448. NHPs were scored by veterinary staff
for clinical signs using an established pharyngitis and tonsillitis scoring system (see
Table S1 in the supplemental material) on days 1, 2, 3, 7, 14, 21, and 28 following
infection. Using a dose of 5 107 CFU, reproducible culture-positive GAS was estab-
lished, and clinical signs of disease were observed (Table S2). This dose was used in
subsequent experiments.
It is well established that as a consequence of natural infection, an immune response
against the preeminent GAS virulence factor, M protein, provides serotype-speciﬁc
protection against the same GAS M serotype (16). Serotype-speciﬁc protection was also
observed in a series of experimental human infections carried out in the 1970s, where
immunization with puriﬁed native M1 protein protected human volunteers against
symptoms of illness, including fever, erythema, and exudative pharyngitis (17). Homol-
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ogous M protein vaccination and challenge are also commonly used as a positive
control in murine vaccination models (18–20). To validate the NHP model as a tool for
GAS vaccine development, we tested whether serotype-speciﬁc protection could be
observed. Rhesus macaques (n 5) were immunized with puriﬁed M1 protein adju-
vanted with alum on weeks 0, 8, and 17. Compared to phosphate-buffered saline
(PBS)-alum negative controls (n 2), speciﬁc anti-M1 antibodies were detected in
serum samples from M1-vaccinated NHPs following primary immunization, and anti-
body titers increased further after booster immunizations (Fig. S1A). At week 20, NHPs
were intranasally infected with 5.2 107 CFU of M1T1 GAS strain 5448 and assessed up
to 28 days postinfection. Body temperature, weight, and white blood cell (WBC) counts
were monitored during GAS pharyngeal infection, which was well tolerated, with no
signiﬁcant clinical indication of an adverse systemic reaction to GAS infection observed
among groups (Fig. S1B to D). Throat swabs taken at various time points during
infection were assigned a colonization score (Table S3) for each individual NHP (Fig. 1A),
in addition to veterinary scoring for pharyngitis and tonsillitis clinical signs (Fig. 1B and
C). Cumulative scores for colonization and tonsillitis were signiﬁcantly lower for NHPs
immunized with puriﬁed M1 protein than for PBS-immunized controls (Fig. 1D and F).
While pharyngitis scores were lower for M1-immunized NHPs than for PBS-immunized
macaques, these did not achieve statistical signiﬁcance (Fig. 1E). Postinfection serum
samples from PBS-immunized NHPs displayed increased anti-M1 antibody titers
(Fig. S1A, shaded area), suggesting the development of serotype-speciﬁc immunity
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FIG 1 M1 immunization protects against GAS colonization in an NHP model for pharyngeal infection. NHPs were immunized on weeks 0, 8, and 17 with M1
(n 5) and PBS (n 2). On week 20, NHPs were intranasally infected with 5 107 CFU of GAS M1T1 5448. Individual NHP identiﬁers are indicated on the left.
(A to C) Individual scores for colonization (A), pharyngitis (B), and tonsillitis (C) were recorded on days 1, 2, 3, 7, 14, 21, and 28 postinfection. (D to F) Log rank
analysis of grouped cumulative scores for colonization (D), pharyngitis (E), and tonsillitis (F) following GAS infection was performed to compare protection
afforded by M1 immunization (red lines) and that in PBS-immunized control NHPs (black lines). Values represent cumulative score percentages standard errors
(SE) (****, P 0.0001).
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following GAS infection of naive NHPs. Taken together, these observations suggest that
the NHP infection model can reproduce vaccine-induced serotype-speciﬁc immunity,
paralleling observations reported in humans and providing a platform to assess the
efﬁcacy of experimental GAS vaccines to prevent pharyngitis.
We next used the NHP infection model to assess the immunogenicity and efﬁcacy
of a non-M protein GAS vaccine. Vaccine candidate Combo5 (18) is composed of ﬁve
GAS protein antigens (arginine deiminase [ADI] [20, 21], trigger factor [TF] [20], C5a
peptidase [SCPA] [22], interleukin-8 [IL-8] protease [SpyCEP] [19], and streptolysin O
[SLO] [19, 23]) with proven protective efﬁcacy in mouse models. This formulation
excludes GAS components M protein and the GlcNAc antigen of group A carbohydrate
that are potentially linked to autoimmune complications in humans (8, 24). NHPs (n 5
per group) were immunized with 100 g of Combo5 (20 g each antigen) or PBS
formulated in alum. Antibody titers against all ﬁve antigens increased following primary
immunization (week 0) and subsequent booster immunizations (weeks 8 and 17) in
Combo5-immunized NHPs (Fig. 2), while antigen-speciﬁc antibody titers remained
unchanged in PBS-alum-immunized NHPs throughout the immunization regime. At
week 20, NHPs were intranasally infected with5 107 CFU of GAS strain 5448 (range,
4.95 107 to 5.22 107 CFU). Similar to the immune response to human GAS infection
(25–27), PBS-alum-immunized NHPs mounted a gradual increase in anti-SCPA, anti-SLO,
and anti-SpyCEP antibody titers following GAS infection (Fig. 2B to D, shaded area). On
the other hand, antibodies against ADI and TF, which are not detected in sera from
convalescent human infection (20), were not elevated in control PBS-alum-immunized
NHPs postinfection (Fig. 2A and E, shaded area). The levels of a select panel of
inﬂammation markers (IL-6, interferon gamma-induced protein 10 [IP-10], IL-1, IL-17A,
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FIG 2 Combo5 antigen-speciﬁc IgG response in NHP serum. Serum samples from Combo5-immunized (n 5) (blue lines) and PBS-immunized (n 5) (black
lines) NHPs were collected before each immunization on weeks 0, 8, and 17; prior to infection on week 20; and postinfection on week 20 (days 1, 2, and 3
postinfection), week 21 (day 7 postinfection), week 22 (day 14 postinfection), week 23 (day 21 postinfection), week 24 (day 28 postinfection), and week 25 (1
week after antibiotic treatment). Antibody titers at the time of infection (week 20) were signiﬁcantly higher for all antigens in Combo5-immunized NHPs than
in PBS-immunized NHPs (P 0.0001). Infection and antibiotic treatment days are marked by red and green arrows, respectively. Duration of GAS infection is
indicated by the gray-shaded area. IgG responses against ADI (A), SCPA (B), SLO (C), SpyCEP (D), and TF (E) were induced in Combo5-immunized NHPs following
immunization. Infection with GAS M1T1 5448 signiﬁcantly raised IgG titers against SCPA (B), SLO (C), and SpyCEP (D) antigens in PBS-immunized NHPs. Values
represent the geometric mean (geomean) titers  geometric SD.
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interferon beta [IFN-], IL-23, tumor necrosis factor alpha [TNF-], IFN-, granulocyte-
macrophage colony-stimulating factor [GM-CSF], IL-8, and monocyte chemoattractant
protein 1 [MCP-1]) measured in NHP serum postchallenge were comparable among all
NHP groups (Fig. S2). Following GAS challenge, body temperature (Fig. 3A), changes in
body weight (Fig. 3B), and white blood cell counts (Fig. 3C) did not differ between
Combo5-alum and PBS-alum groups. Individual scores for colonization (Fig. 3D), phar-
yngitis (Fig. 3E), and tonsillitis (Fig. 3F) were recorded across the course of infection. All
NHPs in this study developed culture-positive GAS infection by day 3 postinfection. Five
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FIG 3 Combo5 immunization reduces pharyngitis and tonsillitis. (A to C) Welfare of NHPs during the course of infection was monitored by measuring rectal
temperature (A), weight (B), and white blood cell counts (C) for PBS-immunized (n 5) (black lines) and Combo5-immunized (n 5) (blue lines) NHPs. Symbols
represent the mean values SD. (D to F) Individual scores for colonization (D), pharyngitis (E), and tonsillitis (F) following infection of Combo5- and
PBS-immunized NHPs with 5 107 CFU of GAS M1T1 5448. Individual NHP identiﬁers are indicated on the left. (G to I) Log rank analysis of grouped cumulative
scores for colonization (G), pharyngitis (H), and tonsillitis (I) following GAS infection was performed to compare protection afforded by Combo5 immunization
(blue lines) to that in PBS-immunized control NHPs (black lines). Values represent cumulative score percentages  SE (*, P 0.05).
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of ﬁve PBS control NHPs and 4/5 Combo5-vaccinated NHPs developed pharyngitis, with
4/5 PBS control and 3/5 Combo5-vaccinated NHPs also developing tonsillitis. While no
difference was observed in cumulative scores for colonization between Combo5-alum-
and PBS-alum-immunized NHPs (Fig. 3G), Combo5 immunization signiﬁcantly reduced
cumulative scores for pharyngitis (Fig. 3H) and tonsillitis (Fig. 3I). All NHPs developed a
signiﬁcant increase in anti-M1 antibody titers in response to infection (Fig. S3). The
increase in antibody titers was comparable between both groups.
The capacity of elicited NHP serum antibodies to bind to the surface of live GAS was
assessed using ﬂow cytometry. Four different GAS serotypes (M1, M3, M12, and M28)
were chosen for this assay, as they are epidemiologically relevant (28) and belong to
different emm clusters (29). Immune sera from Combo5- and full-length M1 protein-
immunized NHPs produced signiﬁcant shifts in ﬂuorescence compared to PBS control
sera for all serotypes examined (Fig. 4A), indicating recognition and binding of antigen-
speciﬁc antibodies to the GAS surface. Immune sera from full-length M1 protein-
immunized NHPs promoted opsonophagocytic killing (OPK) of serotype M1 GAS
(70%), whereas Combo5-alum and PBS-alum sera did not (Fig. 4B). These data suggest
that while Combo5-alum promotes an antibody response that recognizes the GAS cell
surface, the reduction in pharyngitis and tonsillitis afforded by Combo5-alum vaccina-
tion does not depend per se on high levels of opsonic antibody. On the other hand,
vaccination with full-length M1 protein results in opsonic antibody and prevents
colonization by homologous serotype M1 GAS. Opsonic antibodies against M protein
are thought to be a potential correlate of protection in serotype-speciﬁc immunity (16);
however, it is unclear if this paradigm applies to non-M protein antigens. Effector
function assays with Combo5-alum and PBS-alum sera showed that antibodies present
in Combo5-alum sera were able to inhibit red blood cell (RBC) hemolysis by SLO
(Fig. S4A) and IL-8 degradation by SpyCEP (Fig. S4B), virulence mechanisms which
contribute to GAS pathogenesis. While an ideal GAS vaccine would reduce colonization,
Combo5 is the ﬁrst non-M protein vaccine that has shown efﬁcacy in reducing
pharyngitis. Further studies are required to determine the role of opsonic antibodies in
vaccine-induced protection against GAS pharyngitis and colonization.
During the 71st World Health Assembly, the World Health Organization (WHO)
issued a position statement that declares the development of a safe and effective group
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A streptococcal vaccine as one of its priorities in the ﬁght against ARF and RHD (30). We
suggest that evidence of vaccine-induced protection in the NHP model will promote
the development and testing of vaccine candidates in human clinical trials. The NHP
model can be easily exploited to test different vaccines, adjuvants, routes of immuni-
zation, and GAS challenge strains, and the GAS research community could greatly
beneﬁt from its utilization.
MATERIALS AND METHODS
Bacterial strains and growth conditions. For recombinant protein expression, Escherichia coli BL21
Star(DE3) was grown in Luria-Bertani (LB) medium supplemented with ampicillin (100 g ml1) when
appropriate. Streptococcus pyogenes M1T1 strain 5448 is an invasive clinical isolate (31), M3 strain 89437
is a pharyngitis clinical isolate (32), M12 strain HKU16 is a scarlet fever clinical isolate (33), and M28 PS001
is a puerperal sepsis clinical isolate (34). M1 strain M1:43 was used for OPK (kindly provided by S.
Sriskandan). All GAS strains were routinely grown on blood agar plates and in Todd-Hewitt broth
supplemented with 1% (wt/vol) yeast extract (THY). For infection experiments, a master frozen stock of
GAS strain 5448 was prepared and stored at80°C until used for infection. Brieﬂy, GAS M1T1 strain 5448
was cultured overnight on blood agar plates at 37°C and then used to inoculate 15 ml of THY and grown
overnight statically at 37°C. This starter culture was used to inoculate 100 ml of THY to an initial optical
density at 600 nm (OD600) of 0.05 and incubated statically at 37°C until the OD600 reached 0.6. Bacterial
cells were washed twice using ice-cold THY, resuspended in THY supplemented with 15% (vol/vol)
glycerol, aliquoted, snap-frozen in liquid nitrogen, and stored at 80°C. Aliquots were thawed and used
for infection and CFU enumeration.
Antigen expression and puriﬁcation. ADI (D277A), SCPA (D130A S617A), SpyCEP (D151A S617A),
and TF cloned into vector pET151/d-TOPO; SLO (P427L W535A) cloned into vector pET-15b; and M1
cloned into vector pGEX-2T were expressed in E. coli BL21 Star(DE3) cells and puriﬁed by afﬁnity
chromatography as previously described (18). Bacterial endotoxins were removed from all antigen
preparations using immobilized metal ion afﬁnity chromatography (IMAC) by supplementing washing
buffers with 0.1% (vol/vol) Triton X-114 (35). All antigen preparations were ﬁlter sterilized before ﬁnal
formulation. For enzyme-linked immunosorbent assay (ELISA) antigens, tobacco etch virus (TEV) protease
was used to cleave the His tag from ADI, TF, SCPA, and SpyCEP antigens. Uncleaved protein and TEV
protease were removed using IMAC. Thrombin protease was used to cleave the His tag from SLO, and
cleaved SLO was further puriﬁed using size exclusion chromatography.
Animals. Seventeen healthy Indian rhesus macaques (13 females and 4 males; range, 4 to 8 kg) were
used in this study. All animals were housed at the Yerkes National Primate Research Center and were
maintained in accordance with National Institutes of Health guidelines (36). All animal experiments
were approved by the Emory University Institutional Animal Care and Use Committee.
Immunization protocol. NHPs were screened (day7) to conﬁrm the absence of a current or recent
GAS infection. Throat swabs were collected and plated undiluted in Strep Selective II agar (Remel). Serum
samples were collected to conﬁrm the presence of low anti-SLO serum titers using an ASO latex test (ASI)
and of anti-DNase B serum titers using an anti-DNase B antibody ELISA kit (American Research Products,
Inc.) according to the manufacturer’s protocol. The immunization regime consisted of three intramus-
cular (i.m.) injections performed at week 0 (prime), week 8 (boost), and week 17 (boost). Two separate
immunization experiments are described in this work. In the ﬁrst experiment, 5 NHPs were immunized
with 100 g of M1 protein formulated in alum (Alhydrogel 2%; Brenntag Biosector), and 2 NHPs were
immunized with PBS in alum, as a negative control. Serum samples were collected before each
immunization to monitor antigen-speciﬁc antibody responses. Anesthesia using ketamine (10 mg/kg of
body weight i.m.) or tiletamine-zolazepam (Telazol) (5 mg/kg i.m.) was used for all blood and sample
collections. In the second experiment, 5 NHPs per group were immunized via intramuscular injection
with 100 g total protein of Combo5 (20 g each antigen) or PBS as a negative control, both formulated
in alum.
Intranasal GAS infection. Three weeks following the last booster immunization (week 20), NHPs
were challenged with GAS M1T1 strain 5548. On the day of infection, individual aliquots of the GAS
frozen stock were used to infect anesthetized macaques by slowly inoculating 1 ml of the GAS
suspension through the nares. The infecting dose was conﬁrmed by plating diluted aliquots of the
bacterial stock onto blood agar plates. NHPs were monitored on days 1, 2, 3, 7, 14, 21, and 28
postinfection for changes in body temperature, weight gain, and white blood cell (WBC) counts. Throat
swabs were collected at each time point to monitor and score GAS colonization (see Table S3 in the
supplemental material). Veterinary inspection of the oropharynx was undertaken at each time point to
determine tonsillitis and pharyngitis scores using an established grading system (Table S1) (14). Serum
samples were collected at each time point during the course of infection. At the completion of the study
(day 28 postinfection), NHPs were treated daily with penicillin G (30,000 U/kg) via intramuscular injection
for 7 days. At the end of the treatment regime, throat swabs were taken to conﬁrm the culture-negative
status for GAS.
Antigen-speciﬁc ELISA. Antibody titers against individual antigens were determined by an ELISA.
Brieﬂy, proteins (5 g ml1) in carbonate coating buffer (50 mM Na2CO3-NaHCO3, pH 9.6) were adsorbed
to Titertek polyvinyl chloride (PVC) microplates (MP Biomedicals) using 100 l per well (overnight at 4°C).
Plates were blocked using 5% (wt/vol) skim milk in phosphate-buffered saline containing 0.05% (vol/vol)
Tween 20 (PBST) (90 min at 37°C). Plates were washed three times using PBST before the addition of NHP
serum serially diluted in 0.5% (wt/vol) skim milk in PBST (90min at 37°C). Antigen-speciﬁc NHP antibodies
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were detected with horseradish peroxidase (HRP)-conjugated mouse anti-monkey IgG antibody (Southern-
Biotech) at a 1:4,000 dilution (90 min at 37°C). SigmaFast o-phenylenediamine dihydrochloride (OPD)
(Sigma-Aldrich) was used as an HRP substrate, and the absorbance was measured at 450 nm. Endpoint
titers were determined as the highest dilution of serum for which the absorbance was 3 standard
deviations (SD) above the mean optical density of blank wells.
Measurement of inﬂammation markers in NHP serum. Inﬂammation markers present in sera
during the course of infection were detected using the LEGENDplex nonhuman primate 13-plex
inﬂammation panel (BioLegend) according to the manufacturer’s protocol. Samples were acquired using
a BD Accuri C6 ﬂow cytometer (BD Biosciences), and data were analyzed using LEGENDplex data analysis
software (BioLegend). Data for IL-6, IP-10, IL-1, IL-17A, IFN-, IL-23, TNF-, IFN-, GM-CSF, IL-8, and
MCP-1 are presented.
Antibody binding to the GAS surface. GAS strains (M1, M3, M12, and M28 serotypes) were grown
to mid-logarithmic phase (OD600 of 0.6), washed in PBS, resuspended in nonspeciﬁc human IgG (200 g
ml1; Merck Millipore) in PBS with 3% (wt/vol) bovine serum albumin (BSA) (3% BSA–PBS), and incubated
for 1 h at 4°C for blocking. Bacterial cells were washed and resuspended in PBS and adjusted to an OD600
of 0.6. Samples of 100 l were incubated (overnight at 4°C) in triplicate with pooled NHP sera diluted 1:50
in 0.3% (wt/vol) BSA–PBS. Pellets were washed with PBS and resuspended in 100 l of a 1:200 dilution
of mouse anti-monkey IgG conjugated to Alexa Fluor 488 (SouthernBiotech) in 0.3% (wt/vol) BSA–PBS.
Cells were washed with PBS and ﬁxed in 1.5% (wt/vol) paraformaldehyde–PBS. A total of 10,000 events
were acquired using a BD Accuri C6 ﬂow cytometer (BD Biosciences).
Opsonophagocytic killing assay. The OPK assay was adapted for GAS (11) from that previously
developed for Streptococcus pneumoniae (37). Brieﬂy, 10 l of GAS M1 strain M1:43, washed and diluted
to 120,000 CFU per ml in opsonization buffer (10% [vol/vol] deﬁned fetal bovine serum [FBS] [HyClone]
and 0.1% [wt/vol] gelatin [Sigma-Aldrich Company Ltd.] in Hanks’ balanced salt solution [HBSS] with
Ca/Mg), was incubated for 30 min at room temperature with shaking at 700 rpm on a mini-orbital shaker
with 20 l sera and serially diluted in opsonization buffer in a round-bottomed 96-well plate. Ten
microliters of baby rabbit complement, diluted one in six in opsonization buffer, and 40 l differentiated
human promyelocytic leukemia cells (HL-60) were added to each dilution of serum and incubated for
90 min at 37°C with 5% CO2, with shaking at 700 rpm. Prior to the assay, HL-60 cells were differentiated
by incubation in 0.8% dimethylformamide (DMF) at 37°C with 5% CO2 for 5 or 6 days and diluted in
opsonization buffer to 1 107 cells per ml. Plates were then incubated on ice for 30 min, and 10 l from
each well was spotted onto THY agar plates (Todd-Hewitt broth supplemented with 0.5% [wt/vol] yeast
extract [Sigma-Aldrich Company Ltd.] and 1.5% [wt/vol] bacteriological agar [Sigma-Aldrich Company
Ltd.]). An overlay agar, consisting of Todd-Hewitt broth supplemented with yeast extract, 0.75% (wt/vol)
bacteriological agar, and 0.0025% 2,3,5-tetraphenyltetrazolium chloride (Sigma-Aldrich Company Ltd.),
was poured onto each plate. Plates were incubated overnight at 37°C with 5% CO2. The number of
surviving CFU was then counted using a ProtoCOL3 automated colony counter (Synbiosis, Cambridge,
UK), and the dilution of sera resulting in 50% killing was calculated as the opsonic index (OI).
Red blood cell hemolysis. Red blood cells (RBCs) were isolated from whole human blood donated
by volunteers. RBCs were separated from plasma, washed with PBS, and resuspended in the original
blood volume using PBS (100% RBC solution). Combo5-alum and PBS-alum immune sera (100 l) were
serially diluted in PBS before the addition of recombinant SLO (40 ng) in the presence of 2 mM
dithiothreitol (DTT). The mixture was incubated for 1 h at 37°C before the addition of 100 l of the 4%
RBC solution. Reaction mixtures were incubated for 30 min at 37°C. Samples were then centrifuged at
1,000 g for 10 min, and 25 l of the supernatant was diluted in 75 l of PBS. The absorbance was read
at 405 nm. SLO in the absence of immune sera was used as a positive control to calculate 100% hemolytic
activity.
IL-8 degradation. Degradation of IL-8 by GAS was undertaken as previously described (38), with
minor modiﬁcations. Brieﬂy, GAS was grown to mid-logarithmic phase, washed with PBS, and resus-
pended in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with 10% FBS to an OD600 of 0.4.
Combo5-alum and PBS-alum immune sera were added to a ﬁnal dilution of 1:100, and samples where
incubated for 1 h at 4°C before the addition of 80 pg of recombinant IL-8 (BD Biosciences Pharmingen).
Samples were then incubated for 2 and 4 h at 37°C. Supernatants were isolated by centrifugation and
used to determine the residual IL-8 concentrations by an ELISA according to the manufacturer’s protocol
(BD OptEIA).
Statistical analyses. Cumulative scores for colonization, pharyngitis, and tonsillitis were analyzed
using the Mantel-Cox log rank test, with a P value of 0.05 considered statistically signiﬁcant (GraphPad
Prism 7). Log values of antigen-speciﬁc endpoint titers were analyzed using the two-tailed unpaired t
test, with a P value of 0.05 considered statistically signiﬁcant (GraphPad Prism 7). Flow cytometry data
were analyzed using the probability binning algorithm in FlowJo 10.4.1 (Tree Star, Inc.), a cutoff T(X) value
of 200 was experimentally determined, and samples having a T(X) value of 200 were considered
signiﬁcant (P 0.01) (99% conﬁdence). Opsonic index values for each group were analyzed using an
unpaired t test (GraphPad Prism 7), with a P value of 0.05 considered statistically signiﬁcant (95%
conﬁdence). Residual IL-8 concentrations were compared using two-way analysis of variance (ANOVA)
with Sidak’s multiple-comparison test, with a P value of 0.05 considered statistically signiﬁcant (95%
conﬁdence).
Ethics approvals. All animals were maintained in accordance with National Institutes of Health
guidelines (36). All animal procedures were approved by the Emory University Institutional Animal Care
and Use Committee. Human blood donation for use in hemolysis assays was conducted in accordance
with the National Statement on Ethical Conduct in Human Research (39), complied with the regulations
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governing experimentation on humans, and was approved by the University of Queensland Medical
Research Ethics Committee.
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